AAEAAQAAAAAAAARqAAAAJGRiYjY0ZGVjLWMxYTgtNDg3Ny05NmE3LTYzYjdjOWU3ZDkxMw.png

New Data and Award-Winning Research presented on OMNIBotics™ Robotic-Assisted Total Knee Replacement Technology at Two Prestigious Conferences

Posted On October 18, 2016 By OrthoSpineNews In Robotics /

RAYNHAM, Mass., Oct. 18, 2016 /PRNewswire/ — OMNIlife science™, Inc. (“OMNI™”), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announced that several presentations about their OMNIBotics technology were featured early this month at both the International Congress for Joint Reconstruction (ICJR) Transatlantic Orthopaedic Conference in New York City and at the International Society for Technology in Arthroplasty (ISTA) Annual World Congress in Boston. The selection of these papers confirms OMNI’s leadership position in robotic-assisted total knee replacement technology, with more than 10,000 OMNIBotics procedures performed worldwide.

The ICJR focuses on providing a comprehensive orthopaedic learning experience for their members, delivering timely and relevant education. Attendees learned about OMNIBotics technology in an oral poster presentation and three video poster presentations. The oral poster presentation “Surgical Efficiency and Early Patient Satisfaction In Imageless Robotic-Assisted Total Knee Arthroplasty” by John Keggi, M.D., Connecticut Joint Replacement Institute, Hartford, CT was honored with the 2016 Transatlantic Orthopaedic Congress Award of Excellence for an Oral Scientific Poster: Knee, for the exceptional quality of the research presented.

The ISTA Annual World Meeting, with 600 attendees, provides a forum for emerging technologies in orthopaedics to be discussed between surgeons, engineers, and industry with a goal of developing and implementing optimal technologies for patients in a collaborative manner. OMNIBotics was highlighted in three podium presentations and one e-poster combined with a short talk.

Featuring the research of orthopaedic surgeons Leonid Dabuzhsky, M.D. (Melrose-Wakefield Hospital, Boston, MA) and John Keggi, M.D. (Connecticut Joint Replacement Institute, Hartford, CT), presentation topics ranged from studies about the learning curve, surgical efficiency, and patient satisfaction with OMNIBotics robotic-assisted total knee replacement, to their experience with innovative emerging OMNI technologies in ligament tensioning and gap balancing. One study conducted and presented by Dr. Dabuzhsky demonstrated a significant reduction in post-operative manipulation rates when using the OMNIBotics system with ligament balancing versus another competitive technology.

These topics illustrate the interrelationship between technology, clinical efficacy, and value that OMNI believes is vital in the new fiscal paradigm in orthopaedics, the Comprehensive Care for Joint Replacement (CJR) bundled payment model, introduced by the Centers for Medicare and Medicaid Services (CMS) in 2015. OMNI, in conjunction with their consulting surgeon teams, is on the leading edge of developing and using robotic technology to reduce overall cost of joint replacement by improving outcomes without the hospital assuming the burden of a significant capital investment.

“Relevant clinical data was presented at the ISTA and ICJR Meetings, further supporting the OMNIBotics Robotic Assisted Total Knee Replacement procedure as a cost-effective surgical option suited to the value-based hospital reimbursement environment we now serve” commented Rick Randall, OMNI CEO. “Improved OMNIBotics outcomes metrics such as surgical efficiency, post-operative patient satisfaction and reduction in hospital readmissions for costly manipulations under anesthesia were reported from the podium. In addition, promising cadaveric test results using the company’s next generation robotic knee replacement technology for advanced soft tissue balancing were also presented at both meetings”.

About OMNI

OMNI is a privately held company with a proprietary robotic platform, OMNIBotics™, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and improve patient care. For more information about OMNI, please visit www.omnils.com.

Forward-Looking Statements

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms “plans,” “believes” or similar expressions are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release

Contact

Cindy Holloway, Director of Marketing Communications

Phone: (508) 824-2444

cholloway@omnils.com

Logo – http://photos.prnewswire.com/prnh/20161018/429923LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-data-and-award-winning-research-presented-on-omnibotics-robotic-assisted-total-knee-replacement-technology-at-two-prestigious-conferences-300346916.html

Alphatec Spine to Showcase New Minimally Invasive (MIS) and Complex Spine Products at the Upcoming 31st Annual North American Spine Society (NASS) Meeting in Boston

Posted On October 18, 2016 By OrthoSpineNews In Spine /

CARLSBAD, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a provider of spinal fusion technologies, announced today that it will introduce several new products, as well as its current comprehensive portfolio at the upcoming North American Spine Society (NASS) meeting at the Boston Convention and Exhibition Center in Boston, Massachusetts, which will be held from October 26th – 29th, 2016. Alphatec Spine will be located in booth number 1523. In addition, today the Company announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Battalion™ Lateral Spacer System featuring the Alphatec Squadron™ Lateral Retractor.

“We are excited to demonstrate our newest products at NASS this year, including our new lateral system, the Battalion Lateral Spacer System, which features a unique and innovative retractor that we believe offers surgeons improved functionality and better patient outcomes,” said Leslie Cross, Chairman and interim Chief Executive Officer. “Our new XYcor^® Expandable Spinal Spacer System and Arsenal™ Deformity systems will also be showcased. Each of these new products leverage and complement our robust Arsenal Spinal Fixation platform – providing comprehensive and compelling solutions for our surgeon customers and their patients. With our revitalized product pipeline and portfolio, we are increasing our market opportunities in the U.S., including our new offerings in the MIS and complex spine markets, two of the fastest growing market segments of spine.”

Alphatec will be showcasing its broad portfolio of spinal fusion products, including the Company’s newest spinal fusion products:

Alphatec Spinal Fusion Technologies Technical Exhibit Booth #1523:

Battalion Lateral Spacer System and Squadron Lateral Retractor: The Battalion Lateral Spacer System with the Alphatec Squadron Lateral Retractor provides surgeons with a next-generation lateral system with unrivaled, unique design characteristics – total blade control technology that allows the surgeon to maintain approach aperture throughout the procedure, including in-situ blade height adjustment and blade replacement, combined with the Battalion Lateral Spacer will be available in 0°and 15° lordosis with a variety of width and height options for lumbar and thoracic approaches.
XYcor Expandable Spinal Spacer System: The XYcor system provides surgeons with a minimally invasive inspired solution for PLIF and TLIF procedures by utilizing a smaller, more compact ALIF sized implant that can accommodate a variety of patient pathologies. The system provides nearly five times the amount of bone graft potential compared to standard PLIF and TLIF cages.
Arsenal Deformity Spinal Fixation System: The Arsenal Deformity System was thoughtfully designed to provide surgeons with a complete solution to address complex deformity pathologies. The system features unique uniplanar and monoaxial screws, providing the surgeon with easier screw positioning and rod placement through a tulip that has 360 degrees of rotation while restricting motion in the medial/lateral plane for derotation correction.

Alphatec Workshops and Presentations:

“Alphatec Spine Complex Solutions: Avoiding Pitfalls in Complex Deformity”by Dr. Kirkham Wood and Dr. Saechin Kim:
- Wednesday, October 26^th– 8:00am EDT, The Learning Place
“Discover XYcor the New Expandable Spinal Spacer System”by Dr. Henry F. Fabian, Jr.:
- Wednesday, October 26^th– 3:15pm EDT, Alphatec booth #1523
- Thursday, October 27^th– 9:45am EDT, Alphatec booth #1523

About Alphatec Spine

Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a provider of spinal fusion technologies for the treatment of spinal disorders associated with trauma, congenital deformities, disease and degeneration. The Company’s mission is to combine innovative surgical solutions with world-class customer service to improve outcomes and patient quality of life. The Company markets products in the U.S. via a direct sales force and independent distributors.

Additional information can be found at www.alphatecspine.com.

About the North American Spine Society (NASS)

The North American Spine Society is a global multidisciplinary medical society that utilizes education, research and advocacy to foster the highest quality, ethical, value- and evidence-based spine care for patients. The society is comprised of almost 9,000 members worldwide from disciplines including orthopedic surgery, neurosurgery, physical medicine and rehabilitation, pain management, physical/occupational therapy, anesthesiology, radiology and other health care professionals focused on the spine.

Additional information can be found at www.nassannualmeeting.org.

Forward Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include references to the Company’s belief that certain of its products offer competitive functionalities in the marketplace. In addition, forward-looking statements include the Company’s ability to successfully develop and commercialize its current products and new products, including the products discussed in this press release. The words “believe,” “will,” “should,” “expect,” “intend,” “estimate” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to; the uncertainty of success in developing new products or products currently in Alphatec Spine’s pipeline, including without limitation the products discussed in this press release; the uncertainties regarding the ability to successfully license or acquire new products and the commercial success of such products; failure to achieve acceptance of Alphatec Spine’s products by the surgeon community, including without limitation the products discussed in this press release; Alphatec Spine’s ability to develop and expand its U.S. revenues; continuation of favorable third part payor reimbursement for procedures performed using Alphatec Spine’s products, including the products discussed in this press release; unanticipated expenses or liabilities or other adverse events affecting cash flow or Alphatec Spine’s ability to successfully control its costs or achieve profitability; uncertainty of additional funding; Alphatec Spine’s ability to compete with other competing products and with emerging new technologies; product liability exposure and patent infringement claims and claims related to Alphatec Spine’s intellectual property. Please refer to the risks detailed from time to time in Alphatec Spine’s SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K. Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

CONTACT: Investor/Media Contact:

Christine Zedelmayer

Investor Relations

Alphatec Spine, Inc.

(760) 494-6610

czedelmayer@alphatecspine.com

RTI Surgical® Schedules 2016 Third Quarter Earnings and Conference Call for Oct. 25, 2016

Posted On October 18, 2016 By OrthoSpineNews In Financial /

October 18, 2016

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the third quarter 2016 on Tuesday, Oct. 25, 2016, prior to the market open.

RTI will host a conference call and simultaneous audio webcast to discuss second quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International). The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on RTI’s website for one month following the call.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website atwww.sec.gov.

Contacts

RTI Surgical Inc.
Robert Jordheim
Executive Vice President,
Chief Financial Officer
rjordheim@rtix.com
or
Wendy Crites Wacker, APR
Vice President, Global Communications
wwacker@rtix.com
386-418-8888

Nexxt Spine: Taking Action to Reduce Post-Operative Surgical Infection

Posted On October 18, 2016 By OrthoSpineNews In Spine /

Oct 18, 2016 – NOBLESVILLE, Ind. –(BUSINESS WIRE)

Nexxt Spine, LLC, a privately held medical device company dedicated to increasing procedural efficiency and clinical outcomes for patients with debilitating spinal conditions, further demonstrates the company’s on-going commitment toward reducing post-operative surgical infections with the addition of an ISO Class 10,000 (International Standards Organization) Certified Cleanroom for pre-packaging sterile spinal implants within their manufacturing and corporate headquarters located in Noblesville, IN.

Postoperative spine infections have been reported to occur in 1 to 15% of patients after spine surgery. A study of 105 consecutive spine surgeries published in The Spine Journaldemonstrated that spinal implants sterilized following a validated hospital protocol were tested and found to have a contamination rate of 16.7%¹.

“Patient safety is our #1 priority. While multiple factors could contribute to post-operative infection, the authors published data on spinal implants previously assumed sterile and later found to be contaminated,” reports Dr. Robert Wertz, V.P. New Product Development at Nexxt Spine. “We have recently completed certification and validation of our ISO 7, Class 10,000 Cleanroom and will launch our pre-packaged sterile implant initiative parallel to the anticipated FDA clearance of Nexxt Matrixx, a 3-D printed, porous, titanium line of intervertebral spacers used in spine fusion procedures.”

According to Nexxt Spine’s President, Andy Elsbury, “Pre-packaged sterile implants do not require disinfection and steam sterilization prior to use. Implants are individually wrapped in a peel pack tray and sterilized using electron beam (E-beam) radiation. Implant packaging is opened literally seconds prior to implantation. Unlike the reprocessed spinal implants referenced in The Spine Journal study, the risk for implant contamination is virtually non-existent.”

Nexxt Spine will be exhibiting at the 31^st Annual North American Spine Society (NASS) Meeting, October 26-29, 2016, in Boston, MA. To arrange an introductory meeting with a member of Nexxt Spine’s Management Team please contact info@nexxtspine.com.

About Nexxt Spine

Nexxt Spine, LLC is a privately held medical device manufacturer dedicated to increasing procedural efficiency and patient outcomes through development of innovative products, manufactured on the most technologically advanced platforms, and utilizing irreproachable quality standards to treat painful and debilitating spinal pathologies.

Additional information is available online at www.nexxtspine.com.

Reference:

1. Bible, J. E., O’Neill, K. R., Crosby, C. G., Schoenecker, J. G., McGirt, M. J., & Devin, C. J. (2013). Implant contamination during spine surgery. The Spine Journal, 13(6), 637–640. doi:10.1016/j.spinee.2012.11.053

View source version on businesswire.com:http://www.businesswire.com/news/home/20161018005323/en/

Nexxt Spine, LLC
Sarah Caito Koch, 317-436-7801
Scaito@NexxtSpine.com

This article was originally distributed via Business Wire. Business Wire, Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

Tecomet Inc. Announces Acquisition of Mountainside Medical

Posted On October 18, 2016 By OrthoSpineNews In Financial /

WILMINGTON, Mass., Oct. 17, 2016 /PRNewswire/ — Tecomet Inc., a global provider of innovation, design & development services and manufacturing solutions for OEMs in the medical and aerospace & defense industries, today announced the acquisition of Mountainside Medical, a supplier of complex, high precision medical device components and instruments used in minimally invasive surgical devices.

Headquartered in Boulder, CO, Mountainside’s products span across a wide range of precision machined components for the minimally invasive market, including laparoscopic instruments and jaws, orthopedic/neuro-navigation instrumentation, and electrosurgical instruments. The company has invested heavily in research & development, precision machining technology, automation and assembly solutions. Mountainside has developed into a full service manufacturing partner to engineer, design, and manufacture current and next-generation surgical components. The company has a strong pipeline of new products currently in the development stage.

Mark Kemp, Chief Executive Officer, of Tecomet, said, “Achieving a leadership position in the minimally invasive surgical market is a key strategic priority of Tecomet, and the acquisition of Mountainside Medical greatly expands our capabilities and scale in this highly attractive end market. Mountainside’s dedication to innovation, design and development services, prototyping, and precision component manufacturing solutions combined with intimate customer service align perfectly with Tecomet’s strategy and culture. We are excited to partner with Mountainside’s management and employees to further establish collaborative partnerships with new and existing customers.”

Peter Neidecker, Co-Founder of Mountainside, said, “Since my wife Susan and I founded the company we have followed a philosophy of constant innovation. Mountainside’s experienced management team is supported by talented employees who deliver results through a combination of continuous improvement and growth initiatives. With Tecomet’s global footprint, manufacturing capabilities and expertise in design and engineering, Mountainside is very well positioned for future growth.”

About Tecomet
Founded in 1964 and based in Wilmington, MA, Tecomet is a global manufacturer of high precision implants, surgical instruments, trauma plates and photochemical etched products for medical device customers. Tecomet uses its industry-leading prototyping and engineering capabilities to produce highly complex products that provide innovative solutions for its customers’ most demanding products and applications. Tecomet is also a leading manufacturer of precision components to the aerospace & defense industry, producing products used in aircraft engines, missile & satellite propulsion systems, vision systems, and infrared applications. For more information about Tecomet, please visit www.tecomet.com.

Contact: Chris Tofalli
Chris Tofalli Public Relations
914-834-4334

SOURCE Tecomet Inc.

bigstock-Business-Handshake-Agreement-P-83033555-740x431.jpg

INTERMED RESOURCES AND Z-MEDICAL ANNOUNCE AGREEMENT WITH HEALTHTRUST

Posted On October 18, 2016 By OrthoSpineNews In Financial /

11.10.2016

InterMed Resources will distribute spinal implants manufactured by Z-Medical, a company based in Tuttlingen, Germany to HealthTrust (legally known as HealthTrust Purchasing Group, L.P.), a leading group purchasing and total cost management organization that serves nearly 1,600 acute care facilities nationwide.

Under the agreement, Z-Medical will sell its MIS Z-Pedicle Screw System at a contracted price for distribution exclusively through InterMed Resources TN LLC to HealthTrust member facilities throughout the United States.

Z-Medical’s MIS Z-Pedicle Screw System offers surgeons an ideal solution for their indication specific needs. It includes pre-sterilized implants, only one instrument set and an innovative screw design enabling surgeons to efficiently and cost effectively address the most common pathologies. It was designed for a minimally-invasive approach for less tissue disruption, blood loss and trauma and is approved for Degenerative, Trauma, Tumor and Deformity application.

About InterMed Resources TN
InterMed Resources, located in Brentwood, Tennessee, is a minority-owned business that provides national and corporate consulting and contract management services to a variety of medical device manufacturers and suppliers focused on acute care, surgery centers, hospitals, long-term care and physician markets. InterMed specializes in representing innovative medical device companies and suppliers in small and medium business market segments. Its management team has extensive clinical, sales, distribution and national contracting experience (over 50 years collectively) in medical devices.

About Z-Medical
Z-Medical^® GmbH + Co. KG, based in Tuttlingen, Germany, is a privately financed and held medical device company that designs, develops, manufactures and markets innovative implants and surgical instruments in the section of Spine, Hand & Foot and Arthroscopy. The company’s U.S. subsidiary was established in Atlanta, Georgia. Z-Medical implants stand for precision, are sterile packaged and ready for surgery. http://www.z-medicalUSA.com/

Z-Medical is actively recruiting regional distributors to capitalize on this expansion to its hospital network. For Z-Medical information please contact, René Rothacker, Director International Business Development / U.S. Operations, International Cell 0049 170 453 4423, or r.rothacker@z-medical.de

About HealthTrust
HealthTrust (legally known as HealthTrust Purchasing Group, L.P.) is committed to strengthening provider performance and clinical excellence through an aligned membership model and the delivery of total cost management solutions, including supply chain solutions and a contract and service portfolio unparalleled in quality, scope and value. HealthTrust (www.healthtrustpg.com) serves 1,600 acute care facilities, 800 ambulatory surgery centers and members in more than 10,600 other locations, including physician practices, long-term care and alternate care sites. Headquartered in Brentwood, Tennessee, HealthTrust is closely integrated with the proven capabilities of Parallon Business Solutions, LLC (www.parallon.com), a leading provider of healthcare business and operational services, including revenue cycle management, workforce and technology solutions. On Twitter @healthtrustpg and @parallonconnect

Integra LifeSciences Organizes Hands-on Wound Workshop on Best Practices for Omnigraft® Dermal Regeneration Matrix and PriMatrix® Dermal Repair Scaffold at Symposium on Advanced Wound Care (SAWC) Fall Meeting

Posted On October 18, 2016 By OrthoSpineNews In Biologics /

PLAINSBORO, N.J., Oct. 17, 2016 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) recently organized a hands-on regenerative wound management workshop at the Symposium on Advanced Wound Care (SAWC) Fall meeting in Las Vegas, Nevada. The workshop, led by renowned wound care experts John Lantis, MD, and Paul Kim, DPM, focused on best practices for outpatient chronic wound management, including the use of Integra® dermal regenerative technologies in the chronic wound environment. A unique combination of a hands-on skills lab and lecture attracted surgeons, physicians, and mid-level healthcare providers.

“Many chronic wounds need more than just re-epithelialization strategies,” said Dr. Kim, a leading foot and ankle surgeon at Georgetown University Hospital. “This workshop highlighted the importance of good wound care practices, such as good wound bed preparation, to maximize the benefits of dermal regeneration technologies.”

Additionally, nine posters were presented by surgeons and wound care specialists on their latest clinical experiences, using Integra products for wound management. These posters featured the use of PriMatrix for the management of full-thickness chronic wounds and complex pressure ulcer reconstructions as well as a sub-analysis of the Omnigraft® FOot Ulcer New DErmal Replacement (FOUNDER) study.

John Lantis, MD, a leading vascular surgeon at Mount Sinai St Luke’s and Mount Sinai West Hospitals, independently presented his work on using PriMatrix for the management of complex wounds with exposed subcutaneous structures.

“Providing optimal wound care is essential in helping our patients enhance their quality of life,” said Dr. Lantis. “PriMatrix has become an important part of my limb preservation practice and helps me treat patients with very challenging wounds.”

The SAWC serves as a forum to connect physicians, nurses, clinical researchers and scientists with leading experts in wound care, improving patient outcomes through collaboration and education. More than 1,300 healthcare professionals attended the Fall meeting.

About the FOUNDER Study
The FOot Ulcer New DErmal Replacement (FOUNDER) study was a multi-center, randomized, controlled, parallel group clinical trial conducted under an Investigational Device Exemption (IDE). The pivotal clinical trial enrolled 307 patients at 32 sites, and patients were followed for up to 29 weeks. The primary endpoint of the study was the incidence of complete wound closure at 16 weeks. The secondary outcome measures included time to complete wound closure, incidence of recurrence, and quality of life. The median number of applications per patient, including the initial application, for the IDRT group was one. The results from the FOUNDER study were printed in the November/December issue of Wound Repair and Regeneration in the publication, “A Clinical Trial of Integra® Template for Diabetic Foot Ulcer Treatment.”

About Omnigraft® Dermal Regeneration Matrix
Omnigraft® Dermal Regeneration Matrix is the only FDA approved product that regenerates dermal tissue. It is an advanced bi-layer dermal regeneration matrix indicated for use in the treatment of partial and full-thickness neuropathic diabetic foot ulcers (DFUs) that are greater than six weeks in duration, with no capsule, tendon or bone exposed, when used in conjunction with standard diabetic ulcer care. Based on the FOUNDER study, Omnigraft increases the incidence of wound closure by 59%, increases the average rate of wound size closure by 50%, and reduces the median time to wound closure by five weeks, compared to conventional therapy. Additionally, Omnigraft healed patients with fewer applications, with 92% of those who healed requiring two applications or fewer.

About PriMatrix® Dermal Repair Scaffold
PriMatrix® Dermal Repair Scaffold is a unique dermal repair scaffold made with proprietary processing technology that purifies fetal bovine dermis and preserves the beneficial properties of the natural fetal dermal collagen fibers. PriMatrix is indicated for the management of wounds that include: partial and full thickness wounds; pressure, diabetic, and venous ulcers; second-degree burns; surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence); trauma wounds (abrasions, lacerations and skin tears); tunneled/undermined wounds; and draining wounds.

About Integra
Integra LifeSciences Holdings Corporation, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

Investors
Angela Steinway
609-936-2268
angela.steinway@integralife.com  
 
Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com  
 
Media 
Laurene Isip
609-750-7984
laurene.isip@integralife.com

Osteopore International Recognised for Transforming Healthcare With the 2016 Frost & Sullivan Singapore 3D Scaffolds Entrepreneurial Company of the Year Award

Posted On October 18, 2016 By OrthoSpineNews In Biologics /

SINGAPORE, Oct. 14, 2016 /PRNewswire/ — Osteopore International is honoured with the 2016 Frost & Sullivan Singapore 3D Scaffolds Entrepreneurial Company of the Year Award in the Transformational Healthcare category.

This award is presented to Osteopore at the 2016 Frost & Sullivan Singapore Excellence Awards luncheon at the Conrad Centennial Singapore.

Ms. Vandana Iyer, Research Analyst at Frost & Sullivan said that Osteopore’s 3-D scaffold tissue engineering technology platform is uniquely poised above its competitors as it facilitates natural tissue healing and regenerative functions. “The technology comprises novel biomimetic and bioresorbable 3-D printed microstructure implants that can be efficiently used across neurological, craniofacial, maxillofacial, orthopaedic, spinal and dental applications. The company’s innovative 3D scaffold technology also has the potential to address the rising incidence of bone-related injuries and may transform the global bone graft market that is currently valued at around USD5 billion,” she added.

“Osteopore is proud to receive the 2016 Singapore 3D Scaffolds Entrepreneurial Company of the Year Award from Frost & Sullivan. The award is a testament to our vision and ability to transform healthcare with Singapore’s developed medical device technology,” said Mr. Goh Khoon Seng, Chief Executive Officer, Osteopore International.

“Our company has been harnessing 3D printing technology to design, develop and manufacture implantable devices that facilitate natural tissue regeneration, and has delivered successful clinical outcome over the past 10 years. This technology has the potential to minimise or eliminate late morbidity and re-surgery thus reducing cost for healthcare payers and patients,” he added.

The Frost & Sullivan Excellence Awards have identified and honoured best-in class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan’s analysts. Companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry in order to identify best practices.

For the Entrepreneurial Company of the Year Award, Frost & Sullivan analysts independently evaluated two key factors, Entrepreneurial Innovation and Customer Impact.

The Entrepreneurial Innovation criteria that were assessed include market disruption, competitive differentiation, market gaps, Blue Ocean Strategy and passionate persistence.

Customer Impact criteria include price/performance value, customer purchase experience, customer ownership experience, customer service experience and brand equity.

About Osteopore International

Osteopore International, based in Singapore, is the world leader in 3D printed biomimetic and bioresorbable implant devices that empowers the body to regenerate tissue. We collaborate with clinicians and researchers internationally to develop products that address unmet healthcare needs, reduce healthcare cost, improve patient outcomes and enhance lives. For more information, visit us at www.osteopore.com.

Contact : Goh Khoon Seng, (65) 9670-0812, goh_khoon_seng@osteopore.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. For more information, please visit www.frost.com

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com.

SOURCE Osteopore International Pte Ltd

Spineology Completes Limited Release for Elite™ Expandable Interbody Fusion System

Posted On October 17, 2016 By OrthoSpineNews In Spine /

October 14, 2016

MINNEAPOLIS & ST. PAUL, Minn.–(BUSINESS WIRE)–Spineology is excited to announce the successful completion of the Elite™ Expandable Interbody Fusion System limited release. The Elite Expanding Interbody Implant is inserted into the disc space in a contracted minimal height to minimize dissection and neural retraction. It is then incrementally expanded to restore the anatomical height of the space in order to maximize fit and potentially provide indirect neural decompression.

“During the Elite limited release, we took close note of surgeon feedback and what they desired to best treat their patients,” said John Booth, CEO of Spineology. “Observing the surgeon reactions during the limited release and implementing requested enhancements strengthens our belief that Elite will be an exceptional, well received, interbody option in the growing expandable implant market.”

Dr. Mark Grubb of Cleveland, Ohio said, “The ability to deliver an Implant into the disc space at a minimal height in order to limit retraction and reliably control expansion is key in treating patients with spinal disorders. Elite’s instrumentation allows controlled implant delivery and precise height expansion, resulting in an overall effective system.”

Dr. Harel Deutsch of Chicago expressed, “The broad selection of implant heights and lordotic options provide exceptional flexibility and the ability to treat a large range of patients. Additionally, the distraction capabilities and ability to lock the implant at any height during expansion is a feature that further enhances device fit and restoration potential.”

About Spineology

Spineology Inc. provides innovative, anatomy conserving spinal technologies for surgeons and their patients. Spineology surgical techniques conserve spinal bone, ligament and muscle tissue. Spineology is committed to increasing procedural efficiency, reducing surgical morbidity and accelerating patient recovery. Learn more at spineology.com.

Contacts

Spineology Inc.
John Booth, 651-256-8511
jbooth@spineology.com
or
Risdall Public Relations
Dave Folkens, 651-286-6713
dave@risdall.com

aap: Market launch of innovative periprosthetic LOQTEQ® system

Posted On October 17, 2016 By OrthoSpineNews In Extremities /

October 14, 2016

aap Implantate AG (“aap”) announces the market launch of its innovative periprosthetic LOQTEQ® system with the distal lateral femur plate 4.5 PP (periprosthetic). The system is based on a new patent pending fixation technology and enables the treatment of bone fractures in the immediate vicinity of joint implants already existing in the body. Thereby the periprosthetic LOQTEQ® system addresses one of the most demanding procedures in orthopaedics. The distal lateral femur plate 4.5 PP has a CE mark.

Implantations of artificial hip and knee joints are among the most frequent procedures in Germany. With such implantations bone fractures can occur in the immediate vicinity of the treated site during the life of the used joint implants. Treating such fractures poses a particular challenge in orthopaedics because the screws for the bone plates must be fixed around the joint implant. This is where aap’s periprosthetic LOQTEQ® system becomes effective with its innovative fixation technology.

The core of the new technology are special LOQTEQ® hinges that can be fixed to the plate both distally and proximally. They remain flexible within a 45° angle range and are anchored in the bone at a variable angle (±15°) by angle-stable 3.5 mm screws. In this way the fixation can be adapted for a wide range of bone diameters and the plates can be securely fixed past a prosthesis or a nail, especially in an osteoporotic bone. The hinges ensure that the surgeon has maximum flexibility in planning and carrying out the operational stabilisation by means of optional use at the proximal and distal end of the plate. aap’s offering in this area is complemented by cerclage trays for cable or wire cerclages.

In recent months the periprosthetic LOQTEQ® system has proven its worth in clinical initial applications in respect of user friendliness and flexibility. In the future, aap plans to extend the periprosthetic fixation technology to other relevant plates in the LOQTEQ® portfolio for different anatomical regions.

This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap’s public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments

For further information, please contact:

aap Implantate AG
Lorenzweg 5
12099 Berlin

Fabian Franke
Manager Investor Relations
Tel.: +49 (0)30 / 750 19 134
Fax: +49 (0)30 / 750 19 290
Contact

Our Blog

Contacts

Contacts